Lead Program

all catalysts(0)

nothing on the calendar yet

News(10)

• Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
  Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
  biopharma_dive · 1d ago
• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 1d ago
• Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
  Arpeggio Biosciences’ eight-year song has come to an end, as the transcriptome biotech’s CEO admitted the that company’s Nrf2 program had begun to “unravel.”
  fiercebiotech · 1d ago
• Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
  Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in th…
  biospace · 6d ago
• Lilly drops another gene therapy trial from $1B Prevail buyout
  Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.
  fiercebiotech · 6d ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 6d ago
• STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
  The FDA, while promising flexibility in approving Baby KJ-type gene editing, still has set standards difficult for a small startup to meet.
  stat · 7d ago
• J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
  The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
  biopharma_dive · 12d ago
• J&J secures right to take the helm in up to $925M Sail CAR T pact
  As part of the collaboration, Johnson & Johnson will have an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion.
  biospace · 12d ago
• New funding, new jobs: 4 biotechs hiring after series B raises
  Biotechs that announced series B financing this year and are looking for employees as they grow include one that received over $100 million and another that has a partnership with a Big Pharma comp…
  biospace · 12d ago